Related Experiment Video

Updated: Jun 1, 2026

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)
08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)

Published on: May 16, 2012

Inhibition of N-myc downstream-regulated gene 2 in prostatic carcinoma

Chuigong Yu1, Guojun Wu, Nana Dang

  • 1Department of Biochemistry and Molecular Biology; State Key Laboratory of Cancer Biology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.

Cancer Biology & Therapy
|May 31, 2011
PubMed

Insights

N-myc Downstream Regulated Gene-2 (NDRG2) is highly expressed in benign prostate tissue but reduced in prostate cancer (PCA), suggesting it may be a new diagnostic and therapeutic target for PCA.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Prostate carcinoma (PCA) is a significant health concern.
  • Understanding the molecular mechanisms underlying PCA development and progression is crucial for effective treatment strategies.
  • N-myc Downstream Regulated Gene-2 (NDRG2) is a potential tumor suppressor gene.

Purpose of the Study:

  • To investigate the expression of NDRG2 in PCA tissues and cell lines.
  • To explore the clinical and pathological implications of NDRG2 expression in PCA.
  • To evaluate the therapeutic potential of NDRG2 in PCA.

Main Methods:

  • Immunohistochemistry was used to analyze NDRG2 expression in 144 PCA and benign prostatic hyperplasia (BPH) tissues.
  • Western blot was employed to detect NDRG2 and c-Myc levels in prostate cell lines.
  • Adenovirus-mediated NDRG2 was used to assess its effects on PC3 cells and xenografts in vivo, using cell growth curves, tumor growth curves, flow cytometry, TEM, and TUNEL staining.

Main Results:

  • NDRG2 was highly expressed in BPH tissues but significantly downregulated in PCA tissues (p < 0.001).
  • NDRG2 expression negatively correlated with Gleason score (r = -0.445, p < 0.001) and c-Myc levels (r = -0.311, p < 0.001).
  • Adenovirus-mediated NDRG2 suppressed PC3 cell proliferation in vitro and tumor growth in vivo.

Conclusions:

  • NDRG2 downregulation is implicated in prostate carcinogenesis and progression.
  • Adenovirus-mediated NDRG2 demonstrates significant anti-proliferative effects on PCA cells.
  • NDRG2 represents a promising novel target for PCA diagnosis and therapy.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.